Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: Rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial

Clinical and Experimental Nephrology

Volumn 17, Issue 2, 2013, Pages 211-217

  Ueshima, Kenji ^a   Kasahara, Masato ^a   Koya, Daisuke ^b   Babazono, Tetsuya ^c   Sato, Tosiya ^d   Imamoto, Miyuki ^e   Yasuno, Shinji ^a   Fujimoto, Akira ^a   Tanaka, Shiro ^f   Kimura, Genjiro ^g   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^e Kobe Women's Junior College   (Japan)

^f KYOTO UNIVERSITY HOSPITAL   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Atorvastatin; Chronic kidney disease; Estimated glomerular filtration rate; Urinary albumin

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIET THERAPY; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BIOASSAY; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; JAPAN; KIDNEY FUNCTION TEST; METHODOLOGY; MIDDLE AGED; STATISTICAL ANALYSIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; DYSLIPIDEMIAS;

ADULT; AGED; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DYSLIPIDEMIAS; ENDPOINT DETERMINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84878422288     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0676-5     Document Type: Article

References (15)

1. Chhatriwalla AK, Nicholls SJ, Wang TH, Wolski K, Sipahi I, Crowe T, Schoenhagen P, Kapadia S, Tuzcu EM, Nissen SE. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. 2009;53:1110-5.
2. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, J-LIT Study Group. Japan Lipid Intervention Trial: large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J. 2002;66:1096-100.
3. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol. 2004;15:2816-27.
4. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998-1004.
5. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47.
6. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22: 118-27.
7. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131-9.
8. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17: 2006-16.
9. Japanese Society of Nephrology. Chapter 9: evaluation method for kidney function and urinary findings. Clin Exp Nephrol. 2009;13:209-11.
10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-92.
11. Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Tokyo-igakusha; 2009.
12. Japan Atherosclerosis Society. Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. Tokyo: Kyowakikaku; 2007.
13. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206:512-7.
14. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-9.
15. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ. 2008; 336:645-51.